Self Nano-Emulsifying Drug Delivery System (SNEDDS) for Cyproterone Acetate: Formulation, characterization and pharmacokinetic evaluation

IF 2.5 Q2 CHEMISTRY, MULTIDISCIPLINARY

Results in Chemistry Pub Date : 2025-02-11 DOI:10.1016/j.rechem.2025.102118

Nader I. Namazi

{"title":"Self Nano-Emulsifying Drug Delivery System (SNEDDS) for Cyproterone Acetate: Formulation, characterization and pharmacokinetic evaluation","authors":"Nader I. Namazi","doi":"10.1016/j.rechem.2025.102118","DOIUrl":null,"url":null,"abstract":"<div><div>The study aimed to develop a SNEDDS to enhance the solubility and bioavailability of cyproterone acetate (CPA). Various oils, surfactants, and co-surfactants were evaluated for compatibility, with the optimized formulation characterized using Zeta-sizer, FTIR, DSC, and TGA. The SNEDDS was used to study the release and penetration of CPA for two and twenty-four hours, respectively. The lipolysis test, RBC lysis, and pharmacokinetics were among the study subjects. Particle size of 125 ± 5 nm, polydispersity index (PDI) of 0.15 ± 0.01, and zeta potential of −25 ± 2 mV were observed in the SCT3 formulation. The thermal stability and chemical compatibility were demonstrated by FTIR, DSC, and TGA. Ninety percent of the CPA released from SCT3 and 75 % of it permeated. SCT3 digestion produced a significant amount of CPA and minimal RBC lysis in the lipolysis test. The Caco-2 cell viability was 87 % according to the SCT3 SNEDDS. In comparison to the reference formulation, the pharmacokinetics of SCT3 demonstrated enhanced values of C<sub>max</sub>, T<sub>max</sub>, half-life, MRT, AUC, and AUMC. According to our research, the SNEDDS demonstrating high solubility and bioavailability in pharmacokinetic evaluations.</div></div>","PeriodicalId":420,"journal":{"name":"Results in Chemistry","volume":"14 ","pages":"Article 102118"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Results in Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211715625001018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

The study aimed to develop a SNEDDS to enhance the solubility and bioavailability of cyproterone acetate (CPA). Various oils, surfactants, and co-surfactants were evaluated for compatibility, with the optimized formulation characterized using Zeta-sizer, FTIR, DSC, and TGA. The SNEDDS was used to study the release and penetration of CPA for two and twenty-four hours, respectively. The lipolysis test, RBC lysis, and pharmacokinetics were among the study subjects. Particle size of 125 ± 5 nm, polydispersity index (PDI) of 0.15 ± 0.01, and zeta potential of −25 ± 2 mV were observed in the SCT3 formulation. The thermal stability and chemical compatibility were demonstrated by FTIR, DSC, and TGA. Ninety percent of the CPA released from SCT3 and 75 % of it permeated. SCT3 digestion produced a significant amount of CPA and minimal RBC lysis in the lipolysis test. The Caco-2 cell viability was 87 % according to the SCT3 SNEDDS. In comparison to the reference formulation, the pharmacokinetics of SCT3 demonstrated enhanced values of C_max, T_max, half-life, MRT, AUC, and AUMC. According to our research, the SNEDDS demonstrating high solubility and bioavailability in pharmacokinetic evaluations.

Abstract Image